Focus Beyond GLP-1 Therapies: While glucagon-like peptide 1 (GLP-1)-based treatments are a cornerstone for managing cardiometabolic diseases, expanding innovation to address unmet needs remains ...
Relutrigine’s mechanism of precision sodium channel (NaV) modulation is consistent with superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of relutrigine have ...
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage ...